Search Results

You are looking at 1 - 10 of 210 items for :

  • "prophylaxis" x
Clear All
Full access

Brahm H. Segal and Alison G. Freifeld

. Cullen M Steven N Billingham L . Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas . N Engl J Med 2005 ; 353 : 988 – 998 . 6. Lyman GH Kuderer NM Djulbegovic B . Prophylactic granulocyte colony-stimulating factor

Full access

Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis and Brahm H. Segal

agents and diagnostic adjuncts . Clin Infect Dis 2007 ; 44 : 402 – 409 . 3. Segal BH Freifeld AG . Antibacterial prophylaxis in patients with neutropenia . J Natl Compr Canc Netw 2007 ; 5 : 235 – 242 . 4. Kuhlman JE Fishman EK

Full access

Michael Kleinberg

. 4 Bodey GP Rodriguez V Chang HY . Fever and infection in leukemic patients . Cancer 1978 ; 41 : 1610 - 1622 . 5 Cruciani M Rampazzo R Malena M . Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A

Full access

Johan Maertens, Kristel Buvé and Elias Anaissie

safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized double blind study . J Infect Dis 1995 ; 171 : 1545 – 1552 . 3. Cornely OA Ullmann AJ Karthaus M . Evidence-based assessment of

Full access

Alok A. Khorana

individual cancer patients or in specific settings therefore becomes especially important to applying targeted thromboprophylaxis. Knowledge gained within the past decade has improved understanding of risk assessment and prophylaxis of cancer-associated VTE

Full access

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg and Rudolph M. Navari

for patients with cancer. CINV prophylaxis remains the fundamental strategy, because once patients experience CINV they are 4 times more likely to experience nausea and vomiting in subsequent cycles of chemotherapy. 2 Several organizations have

Full access

Myron Goldsmith, George Whitelaw and Denise A. Cannaday

report . Available at : http://www.ahrq.gov/qual/nqfpract.pdf . Accessed July 15, 2008 . 4. Tapson VF Decousus H Pini M . Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients . Chest 2007 ; 132 : 936 – 945

Full access

Cocav A. Engman and Leo R. Zacharski

outpatient chemotherapy . J Thromb Haemost 2007 ; 5 : 632 – 634 . 5. Shen VS Pollak EW . Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980 ; 73 : 841 - 843 . 6. Lee AY Levine MN

Full access

Betsy L. Althaus

prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006 ; 40 : 402 – 407 . 10. Citron ML Berry DA Cirrincione C . Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent

Full access

Eric J. Bow

. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: Cytostatics are a more important risk factor than antibacterial prophylaxis . Clin Infect Dis 1995 ; 20 : 469 – 470 . 10 Bow EJ Loewen R Cheang MS . Cytotoxic